Abcam, ab100545, Human IGF1 ELISA Kit

Size: 1 x 96Tests
Human IGF1 ELISA Kit is a sandwich ELISA designed to quantify Human IGF1 with a sensitivity of 0.2 ng/mL. - Colorimetric sandwich ELISA - 450 nm readout - works on any plate reader - Wide dynamic range - quantifies 0.1 - 30 ng/mL - Cited in over 20 publications
Key facts
Detection method:Colorimetric,
Sample types:Plasma, Cell culture supernatant, Serum,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:< 0.2 ng/mL,
Range:0.1 - 30 ng/mL,
Assay Platform:Microplate

Product details:
Human IGF1 ELISA Kit ab100545 is a sandwich ELISA to measure Human IGF1 in serum, plasma, cell culture supernatant with a sensitivity of 0.2 ng/ml.
How the assay works
This assay employs an antibody specific for Human IGF1 coated on a 96-well plate. Standards and samples are pipetted into the wells and IGF1 present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-Human IGF1 antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of IGF1 bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.
Assay Specificity
Our ELISA kits are rigorously validated to ensure the highest level of consistency and reproducibility. Please check the protocol booklet for more details
Human IGF1 ELISA Kit ab100545 protocol summary
1. Add standard or sample to each well used. Incubate at room temperature
2. Wash and add prepared biotinylated antibody to each well. Incubate at room temperature.
3. Wash and add prepared streptavidin solution. Incubate at room temperature.
4. Add TMB Development Solution to each well. Incubate at room temperature.
5. Add Stop Solution to each well. Read at 450nm immediately.
Get results in 90 minutes with our SimpleStep ELISA
Human IGF1 ELISA Kit (
ab211651
Optimization may be required with urine samples

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The insulin-like growth factor 1 or IGF1 is a protein hormone that plays an important mechanical role in growth and development. Alternative names for IGF1 include somatomedin C. This protein has a mass of approximately 7.6 kDa and is mainly produced by the liver. IGF1 is expressed in a range of tissues including muscle bone and cartilage reflecting its importance in various physiological processes. Its production is stimulated by growth hormone and it acts in an autocrine and paracrine manner to exert its effects.
Biological function summary
IGF1 stimulates growth and proliferation of cells most notably impacting the development of the skeletal system and the regulation of apoptosis. It is not part of a larger protein complex but it interacts closely with IGF1 receptor to execute its functions. By binding to this receptor IGF1 activates intracellular signaling cascades that promote anabolic effects which include increased uptake of glucose and amino acids contributing to muscle and tissue growth.
Pathways
IGF1 operates within the PI3K-Akt and MAPK signaling pathways which are significant for cell survival and proliferation. Its interaction with proteins like IGF binding protein 3 (IGFBP3) modulates its availability and activity in the bloodstream. These pathways are critical for mediating the effects of growth hormone highlighting the role of IGF1 in systemic growth and metabolism regulation.
Alterations in IGF1 levels associate with growth abnormalities such as Laron syndrome and acromegaly. Laron syndrome results from the body's inability to use IGF1 properly due to receptor defects while acromegaly occurs from excessive IGF1 production often due to pituitary tumors. Furthermore aberrant IGF1 signaling connects to cancer development where it can drive tumor growth and metastasis. Drugs targeting IGF1 and its pathway components continue to be researched for therapeutic potential in these conditions.